Benzinga | Aug 18, 2020 05:20AM EDT

Piper Sandler Initiates Coverage On Inozyme Pharma with Overweight Rating, Announces Price Target of $40

Piper Sandler analyst Tyler Van Buren initiates coverage on Inozyme Pharma (NASDAQ:INZY) with a Overweight rating and announces Price Target of $40.